Abeona Therapeutics (NASDAQ:ABEO) Given “Overweight” Rating at Cantor Fitzgerald

Abeona Therapeutics (NASDAQ:ABEO)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report issued on Tuesday, Benzinga reports. They presently have a $18.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price indicates a potential upside of 183.02% from the stock’s current price.

Several other research firms have also issued reports on ABEO. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Wednesday, August 14th. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 10th.

Abeona Therapeutics Stock Down 3.2 %

Shares of ABEO opened at $6.36 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.48 and a current ratio of 7.48. The stock has a market capitalization of $260.52 million, a price-to-earnings ratio of -1.99 and a beta of 1.53. Abeona Therapeutics has a 52 week low of $3.05 and a 52 week high of $9.01. The stock has a fifty day moving average of $5.99 and a 200-day moving average of $5.17.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.42). As a group, sell-side analysts anticipate that Abeona Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in shares of Abeona Therapeutics by 581.6% during the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock valued at $2,134,000 after acquiring an additional 429,456 shares in the last quarter. Simplify Asset Management Inc. acquired a new stake in Abeona Therapeutics in the 2nd quarter valued at $1,732,000. Acadian Asset Management LLC bought a new stake in Abeona Therapeutics during the 1st quarter valued at $91,000. Bank of New York Mellon Corp raised its holdings in Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company’s stock worth $515,000 after buying an additional 2,434 shares during the last quarter. Finally, Rosalind Advisors Inc. lifted its stake in shares of Abeona Therapeutics by 4.7% in the third quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after buying an additional 82,000 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.